Sarcomatoid CarcinomaNCT06950814
Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma
An observational study of Sarcomatoid Carcinoma and Liver Cancer, run by West China Hospital at 1 site in China.
Trial summary
In recent years, researchers have conducted extensive studies on adjuvant therapy following surgical resection of liver cancer, exploring its potential benefits and seeking effective treatment strategies. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Sarcomatoid Carcinoma, Liver Cancer, Adjuvant Therapy
- What is being tested?
- postoperative adjuvant therapy
- Type of treatment
- Surgery or procedure
- How many people
- 50 participants
- Where
- 1 siteChina
- Study dates
- 5 Apr 2025to 5 May 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The data was collected from patients who underwent liver resection and were diagnosed with PHSC pathologically. The data was collected from the division of Liver Surgery of West China Hospital, SCU from December 2018 to May 2023.
Who may be able to join
- patients who underwent liver resection
- patients' postoperative paraffin pathology and immunohistochemistry results were reviewed to identify those diagnosed with PHSC
Who cannot join
- patients who received other anti-tumor treatments before surgery, such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), radiation therapy (RT), and systemic therapy;
- patients diagnosed with other specific types of sarcomas;
- patients with concurrent other malignancies during the course of PHSC;
- patients who were lost to follow-up or lacked essential clinical data.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
West China Hospital
Chengdu, Sichuan, 610041
Jiwei Huang Huang Professor, +86 18980606725, huangjiwei@wchscu.cn
About this study
Official title: Prognostic Impact of Adjuvant Therapy Following Surgical Resection in Primary Hepatic Sarcomatoid Carcinoma: A Retrospective Cohort Study
In recent years, researchers have conducted extensive studies on adjuvant therapy following surgical resection of liver cancer, exploring its potential benefits and seeking effective treatment strategies. Given the rarity and high aggressiveness of primary hepatic sarcomatoid carcinoma, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines. Therefore, we conducted a single-center retrospective study to assess the potential benefits of postoperative adjuvant therapy for patients of primary hepatic sarcomatoid carcinoma.
- Conditions
- Sarcomatoid Carcinoma, Liver Cancer, Adjuvant Therapy
- Being tested
- postoperative adjuvant therapy
- Medical subject headings
- Carcinoma, Liver Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
postoperative adjuvant therapyProcedure or surgery
Given the rarity and high aggressiveness of PHSC, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines.
| Study group | Role | What they receive |
|---|---|---|
| Primary hepatic sarcomatoid carcinoma patients who received adjuvant therapy | Not described Receives: Procedure: postoperative adjuvant therapy | |
| Primary hepatic sarcomatoid carcinoma patients who did not receive adjuvant therapy | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Disease-free survival
Disease-free survival (DFS) was defined as the time from liver resection to disease recurrence or death from any cause.
Measured: From December 2018 to May 2023
Secondary outcomes (1)
Overall survival
Overall survival (OS) was defined as the interval from liver resection to death or the last follow-up.
Measured: From December 2018 to May 2023
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Apr 2025
- Study start5 Apr 2025
- Primary completion3 May 2025 (estimated)
- Study completion5 May 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sarcomatoid CarcinomaStudies of the same condition, open and under way.
- More trials run by West China HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- West China Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jiwei Huang, West China Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06950814
- Sponsor's protocol ID
- JHuang20231
- Status last verified
- Apr 2025
- First submitted
- 22 Apr 2025
- Last updated
- 30 Apr 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prognostic Impact of Adjuvant Therapy Following Surgical Resection in Primary Hepatic Sarcomatoid Carcinoma: A Retrospective Cohort Study
- ClinicalTrials.gov ID
- NCT06950814
- Acronym / sponsor ID
- JHuang20231
- Conditions
- Sarcomatoid Carcinoma, Liver Cancer, Adjuvant Therapy
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- West China HospitalUniversity, hospital or other
- Study start
- 5 Apr 2025 (actual)
- Primary completion
- 3 May 2025 (estimated)
- Study completion
- 5 May 2025 (estimated)
- First posted
- 30 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In recent years, researchers have conducted extensive studies on adjuvant therapy following surgical resection of liver cancer, exploring its potential benefits and seeking effective treatment strategies. Given the rarity and high aggressiveness of primary hepatic sarcomatoid carcinoma, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines. Therefore, we conducted a single-center retrospective study to assess the potential benefits of postoperative adjuvant therapy for patients of primary hepatic sarcomatoid carcinoma.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Primary hepatic sarcomatoid carcinoma patients who received adjuvant therapy | – | Procedure: postoperative adjuvant therapy |
| Primary hepatic sarcomatoid carcinoma patients who did not receive adjuvant therapy | – | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The data was collected from patients who underwent liver resection and were diagnosed with PHSC pathologically. The data was collected from the division of Liver Surgery of West China Hospital, SCU from December 2018 to May 2023.
Key inclusion criteria (2 listed)
- patients who underwent liver resection
- patients' postoperative paraffin pathology and immunohistochemistry results were reviewed to identify those diagnosed with PHSC
Key exclusion criteria (4 listed)
- patients who received other anti-tumor treatments before surgery, such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), radiation therapy (RT), and systemic therapy;
- patients diagnosed with other specific types of sarcomas;
- patients with concurrent other malignancies during the course of PHSC;
- patients who were lost to follow-up or lacked essential clinical data.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| postoperative adjuvant therapyGiven the rarity and high aggressiveness of PHSC, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines. | Procedure or surgery | Primary hepatic sarcomatoid carcinoma patients who received adjuvant therapy |
Primary outcome
Disease-free survival
Time frame: From December 2018 to May 2023
Disease-free survival (DFS) was defined as the time from liver resection to disease recurrence or death from any cause.
1 secondary outcome
Overall survival
Time frame: From December 2018 to May 2023
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Apr 2025.
- Individual participant dataSharing planned: No
Related trials for Sarcomatoid Carcinoma
RecruitingPhase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma
Active, not recruitingPhase 3
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone
RecruitingPhase 2
Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery
Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma
Active, not recruitingPhase 1
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma
Active, not recruitingEarly Phase 1
Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery
Hydronephrosis, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sarcomatoid Carcinoma and Liver Cancer, run by West China Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 30 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jiwei Huang Professor (+86 18980606725, huangjiwei@wchscu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Disease-free survival (time frame: From December 2018 to May 2023). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Apr 2025.